Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P32456

UPID:
GBP2_HUMAN

ALTERNATIVE NAMES:
GTP-binding protein 2; Guanine nucleotide-binding protein 2; Interferon-induced guanylate-binding protein 2

ALTERNATIVE UPACC:
P32456; Q6GPH0; Q6IAU2; Q86TB0

BACKGROUND:
The Interferon-induced guanylate-binding protein 2 (GBP2) is a critical effector in the body's defense against infectious diseases. It operates by hydrolyzing GTP, promoting the destruction of vacuoles containing pathogens, and triggering inflammasome assembly. This process is vital for the immune response to bacterial, viral, and protozoan infections. Beyond its GTPase activity, GBP2 serves as a formidable inhibitor of virus infectivity, including that of Zika virus, by preventing the proper maturation of viral proteins.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Guanylate-binding protein 2 offers a promising avenue for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.